Published in Urology on July 01, 2007
Trends in radical prostatectomy: centralization, robotics, and access to urologic cancer care. Cancer (2011) 3.13
Are hospitals "keeping up with the Joneses"?: Assessing the spatial and temporal diffusion of the surgical robot. Healthc (Amst) (2014) 0.95
Learning curve of robot-assisted laparoscopic radical prostatectomy for a single experienced surgeon: comparison with simultaneous laparoscopic radical prostatectomy. World J Mens Health (2015) 0.75
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst (2006) 6.58
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet (2006) 5.65
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst (2006) 5.42
Imaging use among employed and self-employed urologists. J Urol (2010) 5.34
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol (2007) 5.03
Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol (2011) 5.01
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol (2008) 4.90
Chapter 1: AUA guideline on management of staghorn calculi: diagnosis and treatment recommendations. J Urol (2005) 4.69
Hospital lymph node examination rates and survival after resection for colon cancer. JAMA (2007) 4.55
2007 guideline for the management of ureteral calculi. J Urol (2007) 4.44
Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell (2007) 4.43
Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA (2012) 4.30
Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol (2002) 4.13
Categorisation of complications and validation of the Clavien score for percutaneous nephrolithotomy. Eur Urol (2012) 4.11
Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med (2006) 4.09
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A (2008) 4.07
2007 Guideline for the management of ureteral calculi. Eur Urol (2007) 3.98
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res (2007) 3.82
Partial nephrectomy for small renal masses: an emerging quality of care concern? J Urol (2006) 3.76
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res (2008) 3.59
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol (2007) 3.37
A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res (2008) 3.35
National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? Urology (2006) 3.34
Differential adoption of laser prostatectomy for treatment of benign prostatic hyperplasia. Urology (2013) 3.31
Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst (2003) 3.19
Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA (2013) 3.08
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res (2008) 3.02
Are stone protocol computed tomography scans mandatory for children with suspected urinary calculi? Urology (2011) 2.88
A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res (2008) 2.87
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol (2005) 2.84
The increasing incidence of newborn circumcision: data from the nationwide inpatient sample. J Urol (2005) 2.76
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol (2009) 2.69
Physician-ownership of ambulatory surgery centers linked to higher volume of surgeries. Health Aff (Millwood) (2010) 2.68
Growth of high-cost intensity-modulated radiotherapy for prostate cancer raises concerns about overuse. Health Aff (Millwood) (2012) 2.67
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med (2011) 2.62
Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res (2007) 2.60
Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol (2013) 2.59
JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res (2004) 2.59
Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res (2008) 2.58
Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. J Clin Oncol (2007) 2.53
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res (2009) 2.51
Ex-vivo ureteroscopy at the time of live donor nephrectomy. J Endourol (2011) 2.47
Prospective randomized trial comparing shock wave lithotripsy and ureteroscopy for lower pole caliceal calculi 1 cm or less. J Urol (2008) 2.40
Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia (2006) 2.39
Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol (2004) 2.39
Prostatic fibrosis is associated with lower urinary tract symptoms. J Urol (2012) 2.37
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol (2007) 2.36
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
Pulsed cavitational ultrasound: a noninvasive technology for controlled tissue ablation (histotripsy) in the rabbit kidney. J Urol (2006) 2.35
Nocturia and quality of life: results from the Boston area community health survey. Eur Urol (2011) 2.34
Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys (2006) 2.33
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
Prospective, randomized trial comparing shock wave lithotripsy and ureteroscopy for lower pole caliceal calculi 1 cm or less. J Urol (2005) 2.31
Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population. Urology (2011) 2.26
Urinary tract abnormalities: initial experience with multi-detector row CT urography. Radiology (2002) 2.23
Bladder cancer in 2010: how far have we come? CA Cancer J Clin (2010) 2.21